AWARDS & GRANTS
2019 HUPO Award Recipients
DISTINGUISHED ACHIEVEMENT IN PROTEOMIC SCIENCES AWARD
The Distinguished Achievement in Proteomic Sciences Award recognizes a scientist for distinguished scientific achievements in the field of proteomic science.
(Sponsored by the Journal of Proteome Research - ACS Publications)
Jennifer Van Eyk
Cedars-Sinai Medical Center, USA
Dr. Van Eyk is an extraordinary scientist and a world leader in the area of clinical proteomics. She has a longstanding record of excellence in applying cutting-edge analytical technologies to address clinically relevant biological hypotheses and in translation into clinical therapies or diagnostics. Dr. Van Eyk has pioneered research focusing on understanding the molecular mechanism underlying acute and chronic cardiac disease and the development of clinically robust circulating biomarkers for personalization of medical care. Particularly, she well-known for working on cardiac troponin I and its functionally and clinically important phosphorylation and selective proteolysis that is differentially induced with myocardial ischemia, hemodynamics stress and heart failure.
Dr. Van Eyk is a selfless mentor and a role model especially for women scientists and made tremendous impact in their career development. She has trained 17 MSc/PhD students, 24 post-doctoral fellows and 4 MD’s. Her strengths in leadership, innovation and ability to move discoveries toward the clinic makes Dr. Van Eyk a worthy winner for the HUPO 2019 Distinguished Achievement in Proteomics Science Award.
DISCOVERY IN PROTEOMIC SCIENCES AWARD
The Discovery in Proteomic Sciences Award recognizes a scientist for a single discovery in the field of proteomics.
(Sponsored by Journal of Proteomics - ELSEVIER BV)
Shared by two recipients
Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital in Toronto, Canada
Dr. Gingras is a tenacious scientist with a research focus on protein-protein interactions. Since protein-protein interactions and protein complexes underpin nearly all cellular functions, proteomics must move beyond the description of overall protein identities and abundances to provide a clearer picture of biology. Protein-protein interactions are also often dysregulated in disease such as cancer, and can often be targeted by pharmacological compounds, making them attractive drug targets. Dr. Gingras has contributed to the development of interaction proteomics methods that discriminate between true interactors of a protein and background contaminants. Some of these achievements include detailed experimental protocols and development or co-development of bioinformatics tools that enable improved analysis of protein-protein interactions by the research community. These tools extend her impact to reach beyond her work in unravelling key interaction changes that occur through the activation of signaling pathways in health and disease. Dr. Gingras has published landmark papers that defined the organization of the yeast kinase-phosphatase network, the human HSP90 co-chaperone machinery and the RNA-associated stress granules and P-bodies, to name but a few. For her contribution to the development of multiple methods to study interactomes, HUPO is proud to bestow the 2019 Discovery in Proteomics award to Dr. Gingras.
John R. Yates III
Scripps Research Institute, USA
Professor Yates has significantly contributed to advances in proteomics and protein biochemistry throughout a career spanning more than 35 years which is supported by his outstanding publication record (>123,000 citations, h-index 174). Dr. Yates research spans molecular measurements using mass spectrometry, the earliest bioinformatic tools to interpret this mass spectrometry data, and chemical methods to enhance the coverage and quantification of proteins by mass spectrometry. His latest research is focused on the development and application of mass spectrometry-based proteomic advancements to answer important questions related to cystic fibrosis, Alzheimer’s, schizophrenia and depression. This includes a recent study where he and his team provide comprehensive insights into the molecular disease mechanisms of cystic fibrosis, one of the most common inherited childhood diseases caused by deletion of a single codon for F508 in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, causing loss of function of CFTR, the major cause of cystic fibrosis. These studies also have led to the identification of processes and proteins capable of restoring function to mutated and unfolded proteins in the disease. This discovery has impacted the field of cystic fibrosis and in proteomics by providing a novel approach for the comprehensive identification and analysis of membrane protein interactomes and their dynamics that can be applied to a variety of other studies and potentially help to discover similar disease mechanisms, and it demonstrates the power of intelligent proteomic approaches to answer fundamental questions in biology and medicine. Prof. Yates is an innovative and thought-provoking researcher that has contributed numerous methods to comprehensively study proteomes to highlight the biological context in question in quantitative approaches. We applaud the many achievements to date by Prof John R. Yates III with recognition by the 2019 HUPO Discovery in Proteomics award.
CLINICAL AND TRANSLATIONAL PROTEOMICS AWARD
This award recognizes a scientist in the field of clinical and translational proteomics.
(Sponsored by Clinical Proteomics - BioMed Central)
University of Tübingen, Institute for Ophthalmic Research Centre for Ophthalmology, Germany
Dr. Ueffing has developed research strategies to combine bioanalytic, proteomic, functional genomics and computational research towards investigation of disease mechanisms and markers. His efforts impact clinical proteomics towards understanding and targeting mechanisms of a number of debilitating diseases. Dr. Ueffing has recently co-discovered 3 new rare diseases as ciliopathies using proteomic methods, and he has applied translational bioanalytical and computational approaches towards better diagnostics and therapies for oncological, neurological and neurosensory diseases with a strong focus on uncovering molecular mechanism. In addition, Dr. Ueffing has discovered that the mutant Parkinson disease associated LRRK2 acts as a protein kinase perturbing vesicular trafficking in CNS neurons that has exploited by initiating pharmacological strategies to target LRRK2. Mapping and functionally characterizing large protein networks associated with Parkinson’s disease, syndromic ciliopathies and retinal degeneration, Dr. Ueffing and coworkers have contributed to understand disease on a molecular level and have enabled development of differential clinical diagnosis based on understanding of the impact of mutations and risk variants associated with these diseases discovering new targets for intervention. These achievements allow improved risk prediction and patient stratification according to molecular constraints and rational strategies for therapy development accompanied, and supported, by protein based biosignatures. Dr. Ueffing’s significant contributions to clinical translational efforts utilizing proteomics makes him a most worthy winner of the 2019 HUPO Clinical and Translational Proteomics award.
SCIENCE AND TECHNOLOGY AWARD
The Science and Technology Award recognizes an individual or team in private industry who played a key role in commercialization of a proteomics technology, product, or procedure. The emphasis for the award is on making the technology, product, or procedure widely available, which is different from the basic scientific invention.
(Sponsored by theHUPO Industrial Advisory Board
Scott Tanner, Vladimir Baranov, Olga Ornatsky and Dmitry Bandura
This team, comprising Dr. Scott Tanner, Dr. Vladimir Baranov, Dr. Olga Ornatsky and Dr. Dmitry Bandura, set out in 2005 to apply ICP-MS (TOF) technology in pursuit of high-parameter single cell proteomics. As previous colleagues at MDS Sciex and MDS Proteomics, the four MS technology pioneers set up a lab at the University of Toronto to develop a unique high-parameter mass cytometry. technology that brings unprecedented understanding of single cell proteomics. The technology was originally conceived by the team while working at PerkinElmer-Sciex and at the University of Toronto, and was spun out into a company by the four colleagues, founders of DVS (now part of Fluidigm Inc), that ultimately commercialized the MS-based system called CyTOF and has been described in more than 40 scientific papers related to mass cytometry. The team are the inventors of 44 issued patents and more than 70 pending patent applications.
Over 250 CyTOF systems are in use daily across 4 continents in driving critical biological discoveries. Fluidigm employs nearly 500 people throughout the world supporting the use of Mass Cytometry in the work of some of the leading academic and pharmaceutical organizations globally. The CyTOF technology now drives many applications both in research and Clinical analysis in single cell proteomics including the most groundbreaking work in Immune Oncology, the subject of the 2018 Nobel Prize for Medicine. The ability to monitor biological systems with highly specific prescribed protein markers through the use of metal conjugated antibodies has resulted in incredibly important discoveries that impact cancer, stem cell research, neurology and immunology. In its endeavors to promote Industrial orientated Proteomics based research, HUPO awards the 2019 Science and Technology Award to the worthy winners, Dr’s Tanner, Baranov, Ornatsky and Bandura.
DISTINGUISHED SERVICE AWARD
The Distinguished Service Award recognizes an exemplary member of the proteomic research community whose dedicated service has made indispensable contributions to the organization and mission of HUPO. This award is presented every other year (2013, 2015, 2017, 2019).
Institute for Systems Biology, USA
Dr. Moritz is a world leader in proteomics methods development with a focus on mass-spectrometry applications to comprehensive proteomic quantification and software development for the analysis of Big Data from these comprehensive resources. His group has developed both comprehensive targeted proteomics and methods for whole proteome quantitative measurements using SWATH type approaches. His group develops world-leading pipelines in mass spectrometry data analysis, statistical validation and visualization. His group underpins the MS pillar of HUPO and provides the portal for MS identification data for the Human Proteome Project with PeptideAtlas, and in conjunction with neXtProt. Encompassed in these developments are world-wide accessible web-based resources, and all data and software development tools are both open access and open source for wide dissemination.
Dr. Moritz has served in HUPO as a Council member, Treasurer, Vice President (twice), HUPO IAB Co-chair (twice) as well as the Executive Committee of HUPO. He was co-chair of the 2018 HUPO Congress in Orlando, Florida and assists the many congresses run by HUPO to ensure resources are provided and support is applied when needed. Of particular interest to Dr. Moritz has been his drive to achieve equality in HUPO’s efforts with attention to global inclusion, gender equality and broad and transparent distribution of voting powers amongst its members. Dr. Moritz negotiated with several companies to provide resources to enable HUPO members to freely participate in the HPP Phosphopeptide Challenge. He has also been instrumental in shaping HUPO's future financial status with initiatives in “Development”, strengthening industrial contacts, and in strategic planning to make HUPO a highly successful organization. Based on his scientific credentials and extensive contributions to HUPO and its members over the past several years in a selfless manner, HUPO is proud to award Dr. Moritz with the 2019 Distinguished Service Award.
The HUPO 2019 Organizing Committee is delighted to announce that 157 young researchers from 25 countries have been provided HUPO 2019 Student / ECR Travel Awards to support their participation at this years’ World Congress to be held in Adelaide, Australia from 15-19th September, 2019. We wholeheartedly congratulate these worthy recipients and look forward to welcoming you all to Adelaide!
We also wish to acknowledge our co-funding partners: Australasian Proteomics Society (APS), German Society for Proteome Research (DGPF), Japanese Proteomics Society (JPrOS), Korea HUPO (KHUPO), Proteomics Society of India (PSI), Singapore Society of Mass Spectrometry (SSMS), Swiss Proteomics Society and US-HUPO.
ECR Manuscript Competition
HUPO 2019 - ECR Manuscript Competition: “Proteomics Highlight of the Year”
The Early Career Researcher Initiative of the Human Proteome Organization is pleased to announce the fifth ECR Manuscript Competition to take place at HUPO 2019 in Adelaide, Australia!
The ECR Manuscript Competition was initiated at HUPO 2015 in Vancouver and has been successfully repeated at all following HUPO world congresses. The competition is a unique opportunity to make early-career researchers more visible to the proteomics community. It serves as a platform to highlight the important contributions that postdoctoral fellows, young clinicians and junior faculty members make to the proteomics field. At HUPO 2019 in Adelaide, Australia September 15-19, 2019 we will repeat this successful event.
Three finalists have been selected to present their publications in a related parallel session at HUPO 2019 in Adelaide, where an expert committee will evaluate their oral presentations. Awards (first place USD $1,000 and two runners-up each USD $500) will be presented to the finalists during the Closing Ceremony & Awards Session on September 18, 2019. In addition, the three finalists will receive complimentary registration for HUPO 2019 (registration will be refunded post congress). See who the finalists are below.
Dr. Maggie Lam is an assistant professor in Medicine/Cardiology and Biochemistry at the University of Colorado Denver, Anschutz Medical Campus. Her research develops quantitative proteomics and informatics methods to investigate the mechanisms of heart diseases including cardiac aging, fibrosis, and hypertrophy. In previous work she has published methods to assess the in vivo half-life of mammalian hearts at a proteome scale and developed targeted proteomics workflows to quantify mitochondrial protein phosphorylation events. An ongoing project in her lab aims to identify protein alternative isoform expression in the human heart using a combined transcriptomics and proteomics approach. In parallel, her lab actively works with HUPO to develop algorithms that predict gene-disease relationships and track the research trends of different B/D-HPP topics.
Dr. Ankit Sinha received his Ph.D in cancer proteomics in December 2018 under the supervision of Dr. Thomas Kislinger at the University of Toronto. Dr. Sinha’s doctoral research focused on three key scientific themes with an application of proteomics. Firstly, omics–based technologies are ultra competent for studying longitudinal changes in biological systems1. Secondly, proteomics has the advantage of assaying secreted proteins in an accurate and unsupervised manner2. Lastly, the flow of information in the dogma of biology can differ as genomic clusters converge to different proteomic clusters3. Additionally, during his doctorate, he has contributed to over 20 scientific publications including five publications as the first author. He has received 13 awards throughout his graduate career and recently received the EMBO Long–Term fellowship for post–doctoral training.
To further pursue research training, Dr. Sinha is currently investigating how cancer cells modulate the tumour micro environment and this interdisciplinary research is being conducted with Dr. Felix Meissner (MPI Biochemistry, Munich) and Dr. Dieter Saur (DKFZ/TUM, Munich). The key focus of the investigation is to identify and functionally validate protein markers involved in the development of immune–tolerance of the cancer cells, and the relationship between identified molecular programmes and activated oncogenes. His future career inspiration is to lead a research group as a principal investigator in an academic setting. Dr. Sinha’s career vision is based on the postulation that integration of multi–omic analysis will provide a compendium of data which can provide more accurate biomarker and functionally accurate insights into the flow of biological information in cancer. Ultimately, the systematic integration of various dogma of biology will show that the whole is greater than the sum of its individual parts.
Dr. Eneko Villanueva studied Biology at the Pompeu Fabra University, Barcelona, and later obtained a PhD in Biomedical Research at the University of Barcelona. He spent his PhD studying both the basic way in which viruses evolve to optimise their protein synthesis; as well as learning how to engineer them to constrain their protein synthesis to tumours and develop oncolytic viruses. This combination of basic and applied science resulted in several publications as well as a patent.
At his current position as a Welcome Trust Postdoctoral Fellow in the Cambridge Center for Proteomics in the University of Cambridge, Eneko is trying to follow the “Keep It Simple” paradigm to develop new technologies combining transcriptomics and proteomics to understand the crosstalk between the RNA and the protein worlds. Originally developed as a side project, he recently published OOPS (Orthogonal Organic Phase Separation) method has proved to be of great interest for the cell biology community. By allowing to study RNA-protein interactions in previously inaccessible systems, OOPS is currently used by collaborators in molecular biology, translational medicine and industry, and has also represented a starting point for his current research studying subcellular organisation at spatial and temporal level
HPP Clinical Scientist Travel Grant
|The Human Proteome Project (HPP) was established by the Human Proteome Organization (HUPO) to explore the human proteome and to enable the routine, reliable and broad application of state-of the-art measurements of proteins and proteomes by life scientists and clinicians studying the molecular mechanisms of biological processes and human disease1. This will be accomplished through the generation of laboratory and informational resources that support both research and routine measurement of biological process- and/or disease-relevant proteins2.
To accomplish these goals, the HPP is reaching out again to clinical scientists or clinicians who are using or are considering using proteomics technologies for their research projects. The HPP is supporting five (5) clinician-scientists with a travel grant to attend the 2019 HUPO World Congress in Adelaide, Australia that will take place from September 15-19, 2019.
We are pleased to congratulate the 2019 HPP Clinical Scientist Travel Grant recipients:
1 Aebersold R, Bader GD, Edwards AM, van Eyk JE, Kussmann M, Qin J, Omenn GS. (2013) The Biology/Disease-driven Human Proteome Project (B/D-HPP): Enabling Protein Research for the Life Sciences Community. J Proteome Res. 2013 Jan 4;12(1):23-7. doi: 10.1021/pr301151m.
2 Omenn et al, “HPP Metrics 2018” from JPR 2018 and Paik et al, Editorial, JPR 2018